News

PharmaTher's Deal on Ketamine ANDA Expecting Over $25 Million

PharmaTher's Deal on Ketamine ANDA Expecting Over $25 Million

PharmaTher Sells Ketamine ANDA to Expand Market Potential

PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) recently made a transformative move in the specialty pharmaceutical market by entering a strategic Asset Purchase Agreement for its Abbreviated New Drug Application (ANDA) regarding Ketamine Hydrochloride Injection USP. This deal positions PharmaTher to align with a prominent global pharmaceutical entity known for its expertise in sterile injectables and complex generics.

Insight from the CEO

Fabio Chianelli, the Chief Executive Officer of PharmaTher, expressed enthusiasm about this milestone. He noted that the agreement emphasizes the substantial potential embedded within PharmaTher's ketamine assets. By collaborating with a leading sterile-injectables firm, the company is set to benefit from the anticipated growth in the ketamine market. The structure of this deal not only assures immediate financial support but also provides for future profit-sharing that could drive further growth for the company.

Details of the Agreement

PharmaTher's asset sale involves receiving an upfront cash payment at closing, alongside milestone payments correlated with sales performance. This contract can yield over $25 million, based on various conditional outcomes that hinge on the commercial success of the ANDA product.

Confidentiality and Strategic Positioning

The buyer has requested confidentiality due to strategic reasons related to competitive positioning in the U.S. market for ketamine and sterile injectable generics. Investors should be aware that the buyer is well-regarded in the industry, holding FDA approvals and having successfully secured numerous ANDA approvals in the past. Their expanding U.S. operations include a portfolio of over 40 approved ANDAs, establishing a credible alliance to maximize the prospects for ketamine commercialization.

Future Opportunities for PharmaTher

This agreement is pivotal for PharmaTher, enabling participation in the long-term financial rewards of its ANDA while maintaining a crucial presence in the broader ketamine market. Consequently, the company can prioritize advancing its next-generation therapies, which include long-acting injectables and innovative delivery methods targeted at various conditions, such as psychiatric, pain-related, neurological, and orphan indications.

Anticipated Closing Timeline

As with most business transactions, the deal is subject to customary closing conditions, including necessary regulatory notifications. The expected date of closing is anticipated to occur shortly, promising a timely advancement for PharmaTher and its strategic endeavors.

About PharmaTher Holdings Ltd.

PharmaTher Holdings Ltd. is at the forefront of unlocking the therapeutic potential of ketamine, addressing mental health challenges, pain management, and neurological disorders. To stay informed about PharmaTher's developments, visit PharmaTher.com.

Contact Information

For additional inquiries, please reach out to:
Fabio Chianelli
Chief Executive Officer
PharmaTher Holdings Ltd.
Tel: 1-888-846-3171
Email: info@pharmather.com
Website: www.pharmather.com

Frequently Asked Questions

What is the significance of the recent agreement for PharmaTher?

The agreement allows PharmaTher to monetize its ketamine assets while enabling profit-sharing from sales, enhancing financial stability and growth opportunities.

Who is PharmaTher's partner in the agreement?

The partner is a well-established global pharmaceutical company specializing in sterile injectables and complex generics.

What are the potential earnings from the agreement?

PharmaTher could potentially earn over $25 million through upfront payments, milestone payments, and profit-sharing over a seven-year period.

How will this impact PharmaTher's future projects?

This deal allows PharmaTher to continue focusing on its next-generation ketamine therapies, including innovative treatments for various health conditions.

When is the expected closing date for this agreement?

The closing date is expected to occur in the near term, pending regulatory approvals and other standard conditions.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Servier's Data on Tovorafenib Shows Promise in pLGG

Updated Category News Views 392

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Continue Reading
YSTUDIO's Pens: A Nod to the Power of Writing

Updated Category News Views 404

Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...

Continue Reading
CARsgen's CAR-T Breakthrough on China's Insurance List

Updated Category News Views 291

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

Continue Reading
HONGQI's EHS4 Launch in Europe: Bridging East and West

Updated Category News Views 127

Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 346

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Updated Category News Views 181

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 103

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
PASCAL's Holiday Gift Edit: Timeless Watches Shine

Updated Category News Views 273

Fresh Sparkle for the Holidays Well, here we are again, staring down the barrel of another holiday season. And what do you know, PASCAL is out with its 2026 Holiday Gift Edit, like clockwork. This is the kind of stuff they’re good at—capturing a moment, slapping some color on it, and calling it a game-changer. Launching on November 14, this edit nods to their Timeless...

Continue Reading
Luvme Hair Offers Wig Variety for Winter Fashion

Updated Category News Views 337

Adding Flair to Winter Looks A style kick-off from the fashion world: Luvme Hair is flipping the table on winter wardrobes with a new collection of wigs. As the weather ramps up the need for thick coats and cumbersome layers, these long hairstyles offer a little extra swing, bringing dimension into the mix. Fancy a change from traditional winter hibernation? Here’s what...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 28

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading

Top 5 Most Recently Viewed Articles

IAE International Engine Partnership: Future of Aviation Propulsion

Updated Category News Views 271

IAE International Engine Partnership Reinforces Commitment IAE International Aero Engines (IAE), a collaboration including Japanese Aero Engines Corporation (JAEC), MTU Aero Engines AG (MTU), and Pratt & Whitney, is dedicated to advancing engine technology. Over the years, IAE has been a pillar in the aerospace market, putting forth innovations crucial for commercial...

Continue Reading
Exciting Holiday Attractions Await at Moody Gardens' ICE LAND Exhibit

Updated Category News Views 395

Experience the Magic of the ICE LAND Exhibit at Moody Gardens With the holiday season just around the corner, Moody Gardens is thrilled to announce the opening of its much-anticipated ICE LAND exhibit, themed Pole to Pole. This festive attraction is set to open soon, and it promises to transport visitors on a memorable journey from the icy terrains of the North Pole to...

Continue Reading
PDW Welcomes Dan DeFay as New Vice President of Security

Updated Category News Views 137

PDW Appoints Dan DeFay as Vice President of Information Security PDW has announced the appointment of Dan DeFay as Vice President of Information Security. This is a pivotal role where he will spearhead the company's information security initiatives. Extensive Experience in Cybersecurity Dan DeFay brings over three decades of leadership in cybersecurity and information...

Continue Reading
WITTENSTEIN High Integrity Systems Triumphs with King's Award

Updated Category News Views 192

WITTENSTEIN High Integrity Systems Triumphs with King's Award WITTENSTEIN high integrity systems has achieved a significant milestone by winning the King's Award for Enterprise in the International Trade category. This prestigious honor was officially celebrated with a visit from the Lord-Lieutenant of Somerset, who presented the award at the company’s headquarters in...

Continue Reading
Delta Capital Partners Expands Executive Team for Growth

Updated Category News Views 267

Delta Capital Partners Expands Leadership for Strategic Growth Delta Capital Partners Management, an SEC registered investment adviser specializing in litigation and legal finance, announces exciting changes in its leadership team. The firm welcomes three distinguished professionals: Jason Searfoss as Chief Financial Officer, Elinoar Sofer as Chief Operations Officer, and...

Continue Reading